Brief: Haemonetics Q1 Revenue USD 311.3 Mln
08/08/2023 11:05
Aug 8 (Reuters) - Haemonetics Q1 adjusted EPS USD 1.05 vs. IBES estimate USD 0.73. * Q1 operating income USD 53.7 million * Q1 gross margin 53.7% * Q1 revenue USD 311.3 million vs. IBES estimate USD 292.7 million * Q1 adjusted free cash flow USD 19 million * Q1 EPS USD 0.8
Recent news on Haemonetics
See all newsBrief: Haemonetics Announces FDA Approval Of Perqseal® Elite Vascular Closure System
Haemonetics says FDA clears vascular closure device
US STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Haemonetics surges as CSL plans to move all US plasma centers to its devices